Jan 10, 2023 / 12:30AM GMT
Seiji Wakao - JPMorgan Chase & Co, Research Division - VP
Good afternoon. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan pharma analyst, JPMorgan. It's my great pleasure to introduce Christophe Weber, President and CEO of Takeda. I'm going to pass it to Christophe. Please go ahead.
Christophe Weber - Takeda Pharmaceutical Company Limited - President, CEO & Representative Director
Thank you. It's a great pleasure to be with you this afternoon. Thank you very much for spending your time here with Takeda. We are in a very interesting phase at Takeda after many years of acquisition, integration, business rationalization, we are in a phase where we have a very strong financial foundation, and we are very focused on growth, and we are committed to long-term growth and shareholder return. So a very exciting phase. So I hope that you will share my excitement this afternoon. And actually, investors, the market already took notice. Last year in 2022, our share price increased by 28%. So I think the market is starting to recognize the phase we
Takeda Pharmaceutical Co Ltd at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers